ArticleResearch square2025
β-Glucan Chitosan Particle Provides Cross-Protection Against Multi-Drug- Resistant Candida auris.
Shakti Singh, Ashley Barbarino, Eman G Youssef, Kaustav Das Gupta, Sunna Nabeela, Teclegiorgis Gebremariam, Sondus Alkhazraji, Priya Uppuluri, Garry Ostroff, Ashraf S Ibrahim
Abstract readPreprint
In one paragraphArticle in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
10 authors.
Shakti SinghThe Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center.
Ashley BarbarinoThe Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center.
Eman G YoussefThe Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center.
Kaustav Das GuptaThe Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center.
Sunna NabeelaThe Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center.
Teclegiorgis GebremariamThe Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center.
Sondus AlkhazrajiThe Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center.
Priya UppuluriThe Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center.
Garry OstroffUniversity of Massachusetts Chan Medical School.
Ashraf S IbrahimThe Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center.
Funding
The Effect of Nanoparticle Encapsulated Resveratrol on Treatment of PeriodontitisKL2TR001882 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Elizabeta Nemeth · 2016 to 2026
$13.1MCross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens SupplementR01AI141202 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI IBRAHIM, ASHRAF S. · 2019 to 2023
$5.7MNCATS NIH HHS KL2 TR001882NIAID NIH HHS R01 AI141202
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Candida auriscandidiasiscross-reactivevaccineβ-glucan particle
Identifiers
PMID41356347
PMCPMC12676382
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390